actually not very good data. It’s Finnish data, it’s not American data. So the strength of
that statement is actually somewhat to be challenged, I would say. Do I believe
everybody with diabetes has coronary disease? Well if I believe the whole population in
the world does, yes, but I would argue that I do have some newly diagnosed patients who
maybe don’t need it and I have some people with Type 1 who probably don’t need
but on this recent issue of the CHD risk equivalent, I would remind you that the
American Diabetes Association took a more moderate approach and from what American
Heart or NHLBI has said, and they said that this optional target of 70 is only if you have
diabetes and some other risk factors or clinical evidence of CV disease. So if I have a
newly diagnosed person who has no complications, normal EKG, you know, everything,
I don’t necessarily have to shoot for 70 in that person.
a reliable assessment, when you asked that question of, do we have an example of where
a drug may be at risk in a high risk population but not low risk? One thing I was thinking
about, I mean this is why we are here talking about this, because we haven’t been able to
figure out how to predict cardiovascular disease in diabetes. If we go back to what
In the original data suggesting diabetes as a CHD risk equivalent is
In terms of the other issue and whether or not these low event rates give us
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
look at the placebo group event rate and we can see that. Does that answer the
Levitsky, and then we will go to you. I think Dr. Wyne, did you have a question first?
DR. WYNE: Yeah. I actually had a couple of comments on this subject
DR. BURMAN: Good. I think Dr. Wyne had a question first, Dr.